Therapeutically, HDAC1 and SIRT1 can be targeted using small-molecule inhibitors that disrupt their enzymatic activity, reversing the epigenetic repression of tumor-suppressive miRNAs, including the miR-449 family. This evidence concerns the gene HDAC1 and neoplasm.